Novo nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity

BagsvÆrd, denmark, 24 january 2025 – novo nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular glp-1 and amylin receptor agonist intended for once weekly subcutaneous administration.
NVO Ratings Summary
NVO Quant Ranking